Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 1.00 |
| ▸ | HTR2A | P28223 | 17/20 | 1.00 |
| ▸ | HTR2B | P41595 | 16/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.79 |
| ▸ | HTR1A | P08908 | 1/20 | 0.79 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.79 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.79 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.79 |
| ▸ | CNR1 | P21554 | 1/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.79 |
| ▸ | HRH1 | P35367 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095306 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| SCHEMBL1095307 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL169382 | 0.88 | HTR2A (1.00) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL29349440 | 0.88 | HTR2A (1.00) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL5946555 | 0.88 | HTR2A (1.00) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL1094953 | 0.88 | HTR2A (1.00) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL170848 | 0.88 | HTR2A (1.00) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL16672993 | 0.87 | HTR2A (0.97) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL1954700 | 0.87 | HTR2A (0.97) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL174044 | 0.87 | HTR2A (0.97) | HTR2CHTR2AHTR2BADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160024014-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024014-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-8993750-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993750-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150087634-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS | ARENA PHARMACEUTICALS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-20150087634-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS | ARENA PHARMACEUTICALS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-7977329-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2322162-A1 | 5HT2C receptor modulator compositions and methods of use | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2111859-A1 | 5HT2C receptor modulator compositions and methods of use | Arena Pharmaceuticals, Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1833473-B1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090197868-A1 | 5ht2c receptor modulator compositions and methods of use | ARENA PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197868-A1 | 5ht2c receptor modulator compositions and methods of use | ARENA PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-7514422-B2 | 5HT2c receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514422-B2 | 5HT2c receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070060568-A1 | Obesity therapy; using 3-benzoazepine compound | ARENA PHARMACEUTICALS, A DELAWARE CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060568-A1 | Obesity therapy; using 3-benzoazepine compound | ARENA PHARMACEUTICALS, A DELAWARE CORPORATION | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060568-A1 | Obesity therapy; using 3-benzoazepine compound | HTR2C, HTR3B, HTR3C | HTR2C 1/4885HTR2A 8/4885HTR2B 6/4885 |
| US-20150087634-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2A 2/4885HTR2B 10/4885 |
| US-20160024014-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2C 1/4885HTR2A 2/4885HTR2B 7/4885 |
| US-20090197868-A1 | 5ht2c receptor modulator compositions and methods of use | HTR2C, HTR5A, HTR2A | HTR2C 1/4885HTR2A 3/4885HTR2B 11/4885 |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2C 1/4885HTR2A 2/4885HTR2B 7/4885 |
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2C 1/4885HTR2A 2/4885HTR2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.